Plain-English translation of NCT07540741 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether evolocumab, a newer cholesterol-lowering medicine given by injection, can help people recover better after a stroke caused by blocked arteries. Half of the 1,000 participants will receive evolocumab shots every two weeks (or monthly) plus daily cholesterol pills for 90 days, while the other half will receive only the daily pills. Researchers want to see if the medication helps more people return to normal daily activities.
After a stroke caused by artery blockage, lowering cholesterol is important to prevent another stroke. This study is testing whether this newer cholesterol medication works better than standard treatment alone at helping people recover function and prevent future strokes.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be assigned to either receive the new cholesterol injection plus daily pills, or daily pills alone, based on what your doctor recommends. You'll have clinic visits around day 7 (or at hospital discharge), day 30, and day 90 after your stroke to check how well you're recovering and to monitor for any side effects. The study lasts 90 days total.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Sponsor
First Affiliated Hospital of Harbin Medical University
Enrollment target
~1,000 participants
Started
December 2025
Primary completion
December 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhongling Zhang
First Affiliated Hospital, Harbin Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.